Dr. Lise Høj Omland and colleagues from Rigshospitalet presented new data at the ASCO Annual Meeting 2026 showing how whole genome sequencing can help identify new treatment opportunities for patients with primary CNS tumors, including aggressive brain cancers.
The presented findings are the currently largest single-institution cohort of CNS tumor patients, with a special focus on the molecular landscape of MTAP-deleted tumors.
MTAP deletions are of growing interest because they confer synthetic lethality to PRMT5 inhibitors making tumors vulnerable to this class of targeted therapy. These treatments are currently being investigated in several ongoing phase1/2 trials, both as monotherapy and in combination with other anti-cancer therapies.
The current study utilizes whole genome sequencing to accurately map MTAP status at exon level and identify additional potentially actionable co-mutations that may help guide molecularly matched treatment strategies.
For patients, this means that advanced genetic testing may help identify relevant clinical trials or targeted therapies and researchers are increasingly able to match patients with treatments based on the unique genetic alterations driving their disease.
The whole genome sequencing pipeline at Rigshospitalet, MDxCore is fully integrated into the day-to-day clinical practice, continuously updated with emerging therapeutic targets and remains the most potent tool for matching patients for early stage clinical trials.
The study was presented at ASCO Annual Meeting 2026 and is a collaboration between physicians and researchers at MDxCore, the DCCC Brain Tumor Center, Department of Oncology and The Phase 1 Unit at Rigshospitalet.
Follow this link to see and download the poster